ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.64
0.22%
US Tech 100
20,266.40
0.33%
S&P 500
5,969.34
0.35%
US Dollar vs CAD
1.39805
-0.03%
Bitcoin
98,637.52
-0.40%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Denali Therapeutics Inc (DNLI) Share Price

Denali Therapeutics Inc

Denali Therapeutics Inc (DNLI)

NASDAQ
24.69
0.47
(1.94%)
Closed November 23 3:00PM
Delayed by 15 minutes
24.69
0.00
(0.00%)
After Hours: 6:59PM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
24.69
Bid
23.76
Ask
25.00
Volume
830,355
23.97 Day's Range 24.73
14.56 52 Week Range 33.33
Market Cap
3.553B
Previous Close
24.22
Open
24.32
Last Trade
1
@
25
Last Trade Time
Financial Volume
US$ 20,294,905
VWAP
24.4412
Average Volume (3m)
881,618
Shares Outstanding
143,921,624
Dividend Yield
-
PE Ratio
-24.47
Earnings Per Share (EPS)
-1.01
Revenue
330.53M
Net Profit
-145.22M

About Denali Therapeutics Inc

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates ... Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.denalitherapeutics.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Denali Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker DNLI. The last closing price for Denali Therapeutics was US$24.22. Over the last year, Denali Therapeutics shares have traded in a share price range of US$ 14.56 to US$ 33.33.

Denali Therapeutics currently has 143,921,624 shares outstanding. The market capitalization of Denali Therapeutics is US$3.49 billion. Denali Therapeutics has a price to earnings ratio (PE ratio) of -24.47.

Ask ADVFN Intelligence (AI)

DNLI Latest News

More News

Form 8-K - Current report

November 18 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

November 12 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

November 08 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

November 07 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

November 06 2024
Edgar (US Regulatory)

Form 8-K - Current report

November 06 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

October 22 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

October 21 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

October 18 2024
Edgar (US Regulatory)

Form 8-K - Current report

October 10 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-3.69-13.002114164928.3828.6223.53110348324.42741719CS
4-1.85-6.970610399426.5433.3323.5391950027.3533131CS
120.040.16227180527424.6533.3323.5388161827.91702743CS
264.7924.070351758819.933.3317.9398332224.56556448CS
526.1132.884822389718.5833.3314.56105753021.61355424CS
156-22.39-47.557349192947.0848.4614.5681204325.58375807CS
2607.5944.385964912317.193.9412.3972317132.1747058CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PDYNPalladyne AI Corporation
US$ 4.59
(129.50%)
83M
QMCOQuantum Corporation
US$ 9.11
(126.62%)
39.41M
NANano Labs Ltd
US$ 8.26
(89.02%)
2.03M
XCURExicure Inc
US$ 18.60
(71.27%)
4.36M
SKKSKK Holdings Limited
US$ 1.75
(59.09%)
95.06M
AMIXAutonomix Medical Inc
US$ 6.21
(-54.07%)
946.09k
CETXCemtrex Inc
US$ 0.1146
(-41.74%)
24.39M
MSWMing Shing Group Holdings Ltd
 5.90
(-35.52%)
417.08k
RMSGReal Messenger Corporation
US$ 3.09
(-26.25%)
313.51k
ENSCEnsysce Biosciences Inc
US$ 0.4414
(-25.49%)
4M
ELABElevai Labs Inc
US$ 0.0201
(-0.50%)
425.38M
NVDANVIDIA Corporation
US$ 141.95
(-3.22%)
236.51M
SMCISuper Micro Computer Inc
US$ 33.15
(11.62%)
159.61M
VRPXVirpax Pharmaceuticals Inc
US$ 0.5501
(-6.72%)
159.39M
SOUNSoundHound AI Inc
US$ 8.24
(18.05%)
107.91M

DNLI Discussion

View Posts
Monksdream Monksdream 4 weeks ago
DNLI under $30
👍️0
Monksdream Monksdream 4 weeks ago
DNLI under $30
👍️0
Monksdream Monksdream 2 months ago
DNLI new 52/high
👍️0
conix conix 2 years ago
DNLI on Seeking Alpha

https://seekingalpha.com/article/4570210-denali-need-patient-data-to-justify-that-high-valuation
👍️0
seward seward 2 years ago
Up big, why?
👍️0
seward seward 3 years ago
Up 5 pts AH news or random bid ?
👍️0
seward seward 4 years ago
Add 55.55

Been holding for 100+, flipping small shares
👍️0
seward seward 4 years ago
More flipping.

Filled for one share at 57 this morning. If it hits 62 I can buy coffee.

hans
👍️0
seward seward 4 years ago
Good earnings, flipped some in low 60s
👍️0
seward seward 4 years ago
Adding a little on pullbacks, still looking to hold till it breaks 100 and then sone.
👍️0
seward seward 4 years ago
Best stock I’ve ever seen. Next stop 100 ?
👍️0
seward seward 4 years ago
Up up up. I suppose I should sell it some day. Maybe over 100 ?
👍️0
seward seward 4 years ago
14 may not be in the cards. I may wait for 100.

hans
👍️0
seward seward 5 years ago
Up nice today for no apparent reason.

hans
👍️0
Glider549 Glider549 6 years ago
Interesting .
Stockconsultant daut kom sent me here.
Any debt? Toxic debt?
👍️0
Golden Cross Golden Cross 6 years ago
Back to $14 then do it again!
👍️0
Golden Cross Golden Cross 6 years ago
Looking into if they have a stake in private company Blaze Bioscience and their scorpion venom..GLTA
👍️0
seward seward 6 years ago
In at 14.30, already near 17. Lucky.
👍️0
seward seward 6 years ago
"Announces Advancement and Expansion of Its LRRK2 Inhibitor Clinical Program for Parkinson’s Disease"

I bought some today

hans
👍️0

Your Recent History

NASDAQ
DNLI
Denali Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved